MENU
Showcases Stock ranks Forex

Zentalis Pharmaceuticals Inc (ZNTL)
30.77  0.05 (0.16%) 08-08 16:00
Open: 31.49 Pre. Close: 30.72
High: 31.77 Low: 29.93
Volume: 550,070 Market Cap: 1,753M
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 31.789 - 31.883 31.883 - 31.988
Low: 29.654 - 29.765 29.765 - 29.889
Close: 30.571 - 30.741 30.741 - 30.932
Stock Technical Analysis
Overall:     
Target: Six months: 37.66
One year: 43.98
Support: Support1: 28.41
Support2: 26.05
Resistance: Resistance1: 32.24
Resistance2: 37.66
Pivot: 29.58
Moving Averages: MA(5): 30.38
MA(20): 29.53
MA(100): 29.18
MA(250): 51.74
MACD: MACD(12,26): 0.72
Signal(12,26,9): 0.68
%K %D: %K(14,3): 80.64
%D(3): 76.13
RSI: RSI(14): 58.08
52-Week: High: 87.19
Low: 17.33
Change(%): -40.3
Average Vol(K): 3-Month: 690
10-Days: 521
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ ZNTL ] has closed below upper band by 19.6%. Bollinger Bands are 68.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Sat, 06 Aug 2022
2250 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Prospera Financial Services Inc - Defense World

Sat, 06 Aug 2022
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Holdings Decreased by SG Americas Securities LLC - Defense World

Wed, 03 Aug 2022
2022-08-03 | NDAQ:ZNTL | Press Release | Zentalis Pharmaceuticals Inc. - Stockhouse

Mon, 01 Aug 2022
Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sun, 17 Jul 2022
Insider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) COO Sells $51334.20 in Stock - Defense World

Wed, 13 Jul 2022
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Coverage Initiated at Cowen - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 56.96
Shares Float (M) 32.99
% Held by Insiders 7.49
% Held by Institutions 96.14
Shares Short (K) 6820
Shares Short Prior Month (K) 6270
Stock Financials
EPS -3.820
Book Value (p.s.) 6.920
Profit Margin
Operating Margin
Return on Assets (ttm) -36.7
Return on Equity (ttm) -57.5
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -3.765
Qtrly Earnings Growth
Operating Cash Flow (M) -166.82
Levered Free Cash Flow (M) -97.09
Stock Valuation
PE Ratio -8.05
PEG Ratio
Price to Book value 4.45
Price to Sales
Price to Cash Flow -10.51
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android